Changes to TGA/PBAC parallel processing arrangements for biosimilar medicines

Page last updated: 18 September 2018

Submissions requesting listing of new biosimilar medicines are no longer eligible to be submitted under the TGA/PBAC parallel processing arrangements. These arrangements take effect from the November major submission deadline. Updated TGA/PBAC parallel process guidance and procedures guidance are now available.